ABBV AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About AbbVie (NYSE: ABBV)
›
AbbVie (NYSE: ABBV) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 57,000 employees.
The shares were at 286.20 USD on 20 November 2026, up 32.7% over 52 weeks. Its 52-week range is 190.75 USD to 302.93 USD: the price is 5.5% below the high and 50.0% above the low.
At a market capitalisation of 505.89B USD, it trades at 49.2 times trailing earnings and 17.6 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 25.3, a premium of 95% for ABBV. It pays a dividend yielding 2.44% (it pays out 117% of its earnings), against a median of 2.65% among the dividend payers in that peer group.
AbbVie reports return on equity of -129.2%, an operating margin of 36.6% and revenue up 10.3% year over year.
Its debt exceeds its cash by 70.54B USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 26 analysts cover the stock, with an average rating of Buy; their mean price target of 315.88 USD is 10.4% above the current price. The next earnings report is expected on 3 February 2027.